Join
Live feed
·
PRReleasevia Quantisnow
Kymera Therapeutics Inc. logo

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

ByQuantisnow·Wall Street's wire, on your screen.
KYMR· Kymera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KYMR (Kymera Therapeutics Inc.) and more on Quantisnow.